Ascentage Pharma Group International (HKG:6855)

Market Cap	19.64B +49.0%
Revenue (ttm)	638.89M -41.5%
Net Income	-1.38B
EPS	-3.88
Shares Out	368.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,572,758
Average Volume	2,719,391
Open	53.45
Previous Close	53.35
Day's Range	51.80 - 54.00
52-Week Range	36.50 - 95.35
Beta	0.81
RSI	64.53
Earnings Date	Mar 25, 2026

About HKG:6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 767
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6855

Financial Performance

In 2025, HKG:6855's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY